Interview with Tony Blair on vaccine distribution

The transcript discusses the production of AstraZeneca vaccines for Europe and the UK, emphasizing the need for future preparations against virus mutations. It highlights the importance of shortening the time between identifying new strains and distributing vaccines. The discussion also covers the necessity of global and national strategies and the development of antiviral and biologic capabilities to handle potential vaccine-resistant strains.

How does the mutation of the virus impact vaccine effectiveness?

What are the key preparations needed for dealing with new strains of the virus?

What is the significance of having surveillance in place for new strains?

What challenges might arise if a strain of the virus is not covered by existing vaccines?

Why is it important to develop antiviral capabilities alongside vaccines?